GO:0051424 corticotropin-releasing hormone binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051424 (corticotropin-releasing hormone binding) describes the molecular function of selectively binding corticotropin-releasing hormone (CRH), a 41-amino-acid polypeptide hormone that coordinates the stress response.
• The best-characterized CRH-binding protein is CRHBP, a 37-kDa secreted glycoprotein that sequesters CRH in plasma and brain, thereby buffering hypothalamic-pituitary-adrenal (HPA) axis activation.
• CRHBP is evolutionarily conserved from fish to mammals, and its binding affinity for CRH is in the nanomolar range, allowing it to compete with CRH receptors type 1 and 2.
• Dysregulated CRH-CRHBP interactions have been implicated in stress-related disorders, reproductive physiology, inflammatory pain, and neuroendocrine tumors.
• CRISPR-based knockout, knock-in, and overexpression models of CRHBP and CRH are powerful tools to dissect the functional consequences of CRH binding in vivo and in vitro.
• Understanding GO:0051424 enables target validation for therapeutics aimed at modulating CRH bioavailability in stress, addiction, and metabolic disease.
Description
Corticotropin-releasing hormone (CRH) is a key hypothalamic peptide that initiates the endocrine stress response by stimulating adrenocorticotropic hormone (ACTH) release from the anterior pituitary. The biological actions of CRH are tightly controlled by a secreted binding protein, CRHBP, which binds CRH with high affinity and prevents it from activating CRH receptors. The Gene Ontology molecular function term GO:0051424, corticotropin-releasing hormone binding, captures this essential buffering activity. Researchers studying stress physiology, reproductive biology, and neuropsychiatric disorders increasingly focus on CRHBP because it modulates CRH availability in both circulation and the central nervous system. This article integrates authoritative QuickGO annotation data with verified PubMed literature to provide a research-grade overview of GO:0051424, its genetic players, experimental models, and therapeutic implications.
corticotropin-releasing hormone binding At A Glance
| GO ID | GO:0051424 |
|---|---|
| GO term | corticotropin-releasing hormone binding |
| Ontology | molecular_function |
| Synonym | corticoliberin binding; corticotropin-releasing factor binding; CRF binding; CRH binding |
| Major function | High-affinity binding and sequestration of CRH, regulating its bioavailability and receptor-mediated signaling |
| Major protein | CRHBP (corticotropin-releasing hormone binding protein), a 37-kDa secreted glycoprotein |
| Tissue distribution | Expressed in brain (cortex, hippocampus, amygdala), pituitary, placenta, and plasma |
| Evolutionary conservation | Present from fish to mammals, with conserved ligand-binding domains |
| Related disease | Stress-related disorders, preterm birth, inflammatory pain, and neuroendocrine tumors |
What Is GO:0051424?
GO:0051424 (corticotropin-releasing hormone binding) is a molecular function defined as the selective interaction with corticotropin-releasing hormone (CRH), a polypeptide hormone involved in the stress response that is released by the hypothalamus and stimulates corticotropin release from the anterior pituitary gland. This binding event typically sequesters CRH, preventing receptor activation and modulating downstream neuroendocrine signaling.
Why Is corticotropin-releasing hormone binding Important in Cell Biology?
GO:0051424 is critical because CRH is a central mediator of the stress response, and its binding protein CRHBP acts as a molecular buffer that fine-tunes HPA axis activity. Dysregulation of this binding function has been linked to anxiety, depression, preterm labor, and chronic pain, making it a promising therapeutic target. Moreover, CRHBP is expressed in peripheral tissues and plasma, where it influences inflammatory and metabolic processes beyond the brain. Understanding the precise molecular details of CRH binding is therefore essential for developing interventions that modulate stress-related pathology.
• Regulates the hypothalamic-pituitary-adrenal (HPA) axis by sequestering CRH and preventing excessive ACTH release.
• Modulates reproductive physiology, including placental CRH levels during pregnancy and timing of parturition.
• Influences inflammatory pain responses, as CRH deficiency impairs analgesia in inflammation models.
• Affects dopamine release and reward circuitry, linking CRH binding to addiction and mood disorders.
• Serves as a biomarker in neuroendocrine tumors and stress-related plasma measurements.
• Provides a target for drug discovery aimed at CRH-related GPCR signaling.
• Is evolutionarily conserved, enabling comparative studies from fish to humans.
• Enables precise CRISPR-based modeling of CRH-CRHBP interactions in disease contexts.
Molecular Mechanism of corticotropin-releasing hormone binding
CRH ligand recognition and binding site
In simple terms: CRHBP grabs CRH like a hand fitting into a glove, using a specific pocket on its surface.
CRHBP contains a conserved N-terminal domain that forms a high-affinity binding pocket for CRH. The interaction is non-covalent and reversible, with a dissociation constant in the nanomolar range, allowing CRHBP to compete effectively with CRH receptors. This binding does not require cofactors or post-translational modifications, although glycosylation of CRHBP may influence its stability and secretion.
Sequestration and prevention of receptor activation
In simple terms: By holding onto CRH, CRHBP stops the hormone from reaching its receptors and triggering a stress response.
Once bound, CRH is sterically hindered from interacting with CRH receptor type 1 (CRHR1) and type 2 (CRHR2), both of which are class B GPCRs. This sequestration reduces downstream cAMP accumulation and ACTH secretion in pituitary corticotrophs. In plasma, CRHBP acts as a reservoir, releasing CRH under specific conditions to modulate the free hormone concentration.
Tissue-specific expression and regulation of binding
In simple terms: Different tissues produce different amounts of CRHBP, depending on the body's needs.
CRHBP is expressed in the brain, pituitary, placenta, and liver, with expression levels regulated by stress, glucocorticoids, and inflammatory cytokines. In the chicken telencephalon, CRHBP mRNA shows developmental stage-specific patterns, suggesting roles in neural circuit formation. In humans, plasma CRHBP levels change during pregnancy and in response to acute stress.
Structural features and evolutionary conservation
In simple terms: The shape of CRHBP has been preserved through evolution because it performs a vital job.
CRHBP belongs to the CRHBP family, with a conserved domain architecture including a signal peptide and ten conserved cysteine residues that form disulfide bonds. Orthologs in fish, amphibians, and mammals share significant sequence identity, particularly in the ligand-binding region. This conservation underscores the fundamental importance of CRH binding in vertebrate physiology.
Key Genes Involved in GO:0051424 corticotropin-releasing hormone binding
The following genes and proteins are directly involved in or regulate corticotropin-releasing hormone binding (GO:0051424).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CRHBP | Encodes the primary CRH-binding protein that sequesters CRH | Central to GO:0051424; knockout models show altered stress responses |
| CRH | Encodes the ligand corticotropin-releasing hormone | Ligand for CRHBP; mutations affect binding affinity and HPA axis |
| CRHR1 | CRH receptor type 1; competes with CRHBP for CRH | Target of CRH signaling; binding protein modulates its activation |
| CRHR2 | CRH receptor type 2; alternative receptor for CRH | Modulates stress-coping behaviors; influenced by CRHBP |
| UCN | Urocortin, a CRH-related peptide | Can bind CRHBP with lower affinity; expands functional repertoire |
| UCN2 | Urocortin 2, selective CRHR2 agonist | Not a primary CRHBP ligand but relevant to stress circuitry |
| UCN3 | Urocortin 3, another CRHR2 agonist | May interact with CRHBP in specific tissues |
| POMC | Pro-opiomelanocortin, precursor of ACTH | Downstream of CRH signaling; CRHBP modulates its processing |
| NR3C1 | Glucocorticoid receptor | Feedback regulator of CRH and CRHBP expression |
| FKBP5 | Co-chaperone regulating glucocorticoid receptor | Modifies stress axis sensitivity and CRHBP function |
| AVP | Arginine vasopressin, synergizes with CRH | Modulates HPA axis; CRHBP may influence AVP-CRH balance |
| GABRA1 | GABA receptor subunit | Indirectly affects CRH neuronal activity and CRHBP release |
| BDNF | Brain-derived neurotrophic factor | Regulates stress plasticity; interacts with CRH system |
| TPH2 | Tryptophan hydroxylase 2 | Serotonin synthesis; modulates CRH and CRHBP in raphe |
| SLC6A4 | Serotonin transporter | Affects CRH release and CRHBP levels in limbic regions |
| ESR1 | Estrogen receptor alpha | Regulates CRHBP expression in reproductive tissues |
| PGR | Progesterone receptor | Influences placental CRHBP and CRH balance |
How Is corticotropin-releasing hormone binding Regulated?
CRHBP expression and CRH binding are regulated at multiple levels. Glucocorticoids, acting through NR3C1, modulate CRHBP transcription in a tissue-specific manner. In the placenta, estrogen and progesterone influence CRHBP and CRH production, contributing to the timing of parturition. Inflammatory cytokines such as IL-6 can alter CRHBP levels during acute stress. Additionally, CRHBP secretion is affected by glycosylation and proteolytic processing. At the protein level, CRHBP binding to CRH is pH- and temperature-sensitive, with optimal binding at physiological pH. These regulatory layers ensure that CRH bioavailability is finely tuned to environmental and physiological demands.
corticotropin-releasing hormone binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CRHBP | Major depressive disorder, anxiety | CRHBP knockout mice; stress-induced behavioral tests |
| CRH | Inflammatory pain, Cushing's syndrome | CRH knockout or point-mutation models; CFA inflammation |
| CRHR1 | Alcohol dependence, stress disorders | CRHR1 knockout; CRHBP overexpression to reduce signaling |
| ESR1 | Preterm birth, endometriosis | Placental cell models with ESR1 knockdown |
| FKBP5 | PTSD, depression | FKBP5 knockout; CRHBP expression profiling |
Stress-related psychiatric disorders
Alterations in CRHBP levels have been observed in individuals with major depressive disorder, anxiety, and post-traumatic stress disorder. Because CRHBP buffers CRH, reduced binding capacity may lead to HPA axis hyperactivity, a hallmark of these conditions. Genetic variants in CRHBP have been associated with differential stress responses, making it a candidate for precision psychiatry.
Reproductive and pregnancy complications
During pregnancy, placental CRH and CRHBP levels rise exponentially. An imbalance in the CRH-to-CRHBP ratio has been linked to preterm birth and preeclampsia. CRHBP may serve as a biomarker for predicting labor onset and pregnancy-related disorders.
Inflammatory and neuropathic pain
CRH deficiency impairs analgesic responses during inflammation, and CRHBP modulates the availability of CRH at sites of inflammation. In animal models of CFA-induced inflammation, CRHBP knockout mice show altered pain sensitivity, suggesting a role for CRH binding in nociception.
Neuroendocrine tumors and cancer
CRHBP is expressed in various neuroendocrine tissues and tumors, where it may influence hormone secretion and tumor growth. Ectopic CRH production in tumors can lead to Cushing's syndrome, and CRHBP may modulate the bioactivity of tumor-derived CRH.
From corticotropin-releasing hormone binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CRHBP loss alter HPA axis reactivity? | CRHBP knockout mouse (constitutive or conditional) |
| How does a CRH point mutation affect CRHBP binding? | CRH point-mutation knock-in mice or cell lines |
| Can CRHBP overexpression buffer chronic stress? | CRHBP overexpression transgenic mouse or AAV delivery |
| Where is CRHBP expressed during development? | Tagged knock-in reporter (e.g., GFP-CRHBP) in chicken or mouse |
| What is the effect of CRHBP on inflammatory pain? | CRHBP knockout in CFA-induced inflammation model |
| Does CRHBP modulate dopamine release? | CRHBP knockout with microdialysis in healthy individuals |
How to Study the corticotropin-releasing hormone binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity (KD) and kinetics | CRH-CRHBP interaction analysis |
| Isothermal titration calorimetry (ITC) | Thermodynamics of binding | Quantifying CRHBP-CRH binding |
| Radioligand binding assay | Competitive binding and receptor occupancy | Tissue-specific CRHBP levels |
| RNA-seq | CRHBP mRNA expression | Tissue and developmental profiling |
| CRISPR knockout | Loss-of-function phenotypes | HPA axis and behavioral studies |
| CRISPR knock-in | Point mutations in CRH or CRHBP | Structure-function analysis |
| PET imaging | CRH release in vivo | Human stress studies |
| Microdialysis | Dopamine and CRH levels | Neurochemical correlates of binding |
CRISPR knockout and knock-in models
CRISPR-Cas9 can generate CRHBP or CRH knockout cell lines and animal models to study the loss of binding function. Knock-in of point mutations in the CRH-binding domain of CRHBP allows precise structure-function analysis. These models are essential for validating the role of GO:0051424 in stress-related phenotypes.
Biochemical binding assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) measure the affinity and kinetics of CRH-CRHBP interactions. Radioligand binding assays using 125I-CRH are classic methods to quantify binding in tissue extracts. These techniques provide direct evidence for GO:0051424 activity.
Transcriptomic and proteomic profiling
RNA-seq and quantitative proteomics can assess CRHBP expression changes across tissues and conditions. Single-cell RNA-seq reveals cell-type-specific expression of CRHBP in the brain and pituitary. Proteomic analysis of plasma can quantify CRHBP levels as a biomarker.
Behavioral and neuroendocrine phenotyping
CRHBP knockout mice can be subjected to stress paradigms (e.g., forced swim, restraint) with measurements of corticosterone and ACTH. In humans, CRH and dopamine release can be assessed using PET imaging and microdialysis. These methods link molecular binding to physiological outcomes.
How CRISPR Can Be Used to Study GO:0051424 corticotropin-releasing hormone binding
Knockout
CRISPR-Cas9 knockout of CRHBP or CRH eliminates the binding function of GO:0051424, allowing researchers to observe downstream effects on HPA axis activity, stress behavior, and pain sensitivity. Knockout cell lines are also useful for biochemical assays to confirm the absence of CRH binding.
Point Mutation
Introducing point mutations in the CRH-binding domain of CRHBP (e.g., altering key cysteine residues) can disrupt binding without affecting protein stability. Such models help map the precise residues required for GO:0051424 and distinguish binding from other functions.
Knock-in
Knock-in of tagged CRHBP (e.g., HA or GFP) enables visualization and pull-down of the binding protein in native tissues. Knock-in of human CRHBP variants can model genetic susceptibility to stress disorders.
Overexpression
Overexpression of CRHBP using transgenic or viral vectors increases CRH sequestration, reducing free CRH levels. This approach can test whether enhancing GO:0051424 activity protects against stress-induced pathology.
How EDITGENE Supports corticotropin-releasing hormone binding Research
Researchers studying corticotropin-releasing hormone binding-related genes often need to determine whether a candidate gene is causally involved in stress regulation, reproductive biology, or pain pathways. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell and animal models, enabling rigorous functional validation of GO:0051424 and its associated genes.
Contact EDITGENE today to design your custom CRISPR model for corticotropin-releasing hormone binding research.
Frequently Asked Questions About corticotropin-releasing hormone binding
What is corticotropin-releasing hormone binding (GO:0051424)?
It is a molecular function defined as the selective interaction with corticotropin-releasing hormone (CRH), typically by the CRH-binding protein (CRHBP), to sequester CRH and modulate its availability.
What genes are involved in corticotropin-releasing hormone binding?
The primary gene is CRHBP, which encodes the binding protein. Other related genes include CRH (the ligand), CRHR1, CRHR2, and UCN.
How does CRHBP regulate the stress response?
CRHBP binds CRH with high affinity, preventing it from activating CRH receptors and thereby buffering the HPA axis and reducing ACTH release.
What diseases are associated with CRH binding dysfunction?
Dysregulation has been linked to major depressive disorder, anxiety, preterm birth, inflammatory pain, and neuroendocrine tumors.
What experimental models are used to study CRH binding?
Common models include CRHBP knockout mice, CRH point-mutation knock-in mice, and cell lines with CRISPR-mediated modifications.
How can CRISPR be used to study GO:0051424?
CRISPR can create knockout, knock-in, or overexpression models of CRHBP and CRH to dissect the functional consequences of CRH binding in vitro and in vivo.
Is CRHBP conserved across species?
Yes, CRHBP is evolutionarily conserved from fish to mammals, with conserved ligand-binding domains.
What is the affinity of CRHBP for CRH?
CRHBP binds CRH with nanomolar affinity, allowing it to compete effectively with CRH receptors.
Where is CRHBP expressed?
CRHBP is expressed in the brain (cortex, hippocampus, amygdala), pituitary, placenta, and liver, and is secreted into plasma.
Can CRHBP be targeted therapeutically?
Yes, modulating CRHBP levels or binding affinity is a potential strategy for treating stress-related disorders and inflammatory pain.
Conclusion
GO:0051424 (corticotropin-releasing hormone binding) represents a critical molecular function that governs the bioavailability of CRH, a master regulator of the stress response. The binding protein CRHBP acts as a buffer, and its dysfunction is implicated in psychiatric, reproductive, and inflammatory disorders. Advances in CRISPR-based genome editing now allow precise interrogation of CRHBP and CRH in physiologically relevant models, paving the way for novel therapeutics. EDITGENE's comprehensive services support every step of this research journey, from knockout to bioinformatics.
References
- 1. Ketchesin KD et al.. 2017. Corticotropin-releasing hormone-binding protein and stress: from invertebrates to humans.. Stress 20(5):449-464 PMID: 28436309
- 2. Zhao XJ et al.. 1997. Corticotropin-releasing hormone-binding protein and its possible role in neuroendocrinological research.. Horm Metab Res 29(8):373-8 PMID: 9288573
- 3. Vitoratos N et al.. 2006. "Reproductive" corticotropin-releasing hormone.. Ann N Y Acad Sci 1092:310-8 PMID: 17308156
- 4. Seasholtz AF et al.. 2002. Corticotropin-releasing hormone-binding protein: biochemistry and function from fishes to mammals.. J Endocrinol 175(1):89-97 PMID: 12379493
- 5. Metwalli AH et al.. 2023. Mapping of corticotropin-releasing factor, receptors, and binding protein mRNA in the chicken telencephalon throughout development.. J Comp Neurol 531(14):1389-1424 PMID: 37393534
- 6. Payer D et al.. 2017. Corticotropin-releasing hormone and dopamine release in healthy individuals.. Psychoneuroendocrinology 76:192-196 PMID: 27951520
- 7. Karagianni E et al.. 2024. Corticotropin-releasing hormone deficiency results in impaired analgesic response during CFA-induced inflammation.. Hormones (Athens) 23(3):535-545 PMID: 38740711
- 8. Hemley CF et al.. 2007. Corticotropin releasing hormone--a GPCR drug target.. Curr Drug Targets 8(1):105-15 PMID: 17266535
